Summary
14C-radiolabeled (radiocarbon) drug studies are central to defining the disposition of therapeutics in clinical development. Concerns over radiation, however, have dissuaded investigators from conducting these studies as often as their utility may merit. Accelerator mass spectrometry (AMS), originally designed for carbon dating and geochronology, has changed the outlook for in-human radiolabeled testing.
Register to download
Opportunities in low-level radiocarbon microtracing: applications and new technology
You may also be interested in:
Fact Sheet
Central Review Services
PRA's Central Review Services team, unique in the CRO industry, offers lupus-specific expertise in efficacy endpoint data correlation, standardized…
View Resource
Blog
Winning Team: Working With a Service Dog
Read Story
Poster
Pharmacokinetic Charcateristic of Oral_Intranasal Morphine ARER
Extended-release (ER) opioid formulations are often targeted for misuse and abuse because they contain high amounts of opioid. An oral…
View Resource
View all related content and resources for Scientific Affairs
Explore Insights